MAPT and Alzheimer disease: Because CSF p-tau is an important biomarker in the workup for AD and is incorporated in its diagnostic criteria,17 it is of great importance to determine which of these p-tau variants to use, especially as clinical heterogeneity and different stages in AD may be determined by heterogeneity in the post-translational modification (PTM) of tau.18